臨床整形外科59巻4号

2024年04月発行

特集 脊椎関節炎SpAを理解する—疾患概念・診断基準・最新治療

体軸性脊椎関節炎(axSpA)の治療

著者： 浅井秀司¹ 鈴木望人¹ 岸本賢治² 今釜史郎¹

所属機関： ¹名古屋大学医学部整形外科 ²西尾市民病院整形外科

ページ範囲：P.353 - P.359

本邦では，2010年にTNF阻害薬が強直性脊椎炎に対して承認され，続いてIL-17阻害薬とJAK阻害薬が強直性脊椎炎およびX線基準を満たさない体軸性脊椎関節炎に対して承認された．これらの分子標的薬の登場により，体軸性脊椎関節炎患者の症状や炎症をコントロールできるようになった．一方で，体軸性脊椎関節炎において薬物治療による構造的破壊の進行抑制に関する十分なエビデンスはない．治療目標である「QOLを最大化する」ためには，薬物治療のみならず患者教育，運動などの非薬物治療も必要不可欠である．

参考文献

1) Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis:2022 update. Ann Rheum Dis 2023;82(1):19-34.

2) Chung HY, Machado P, van der Heijde D, et al. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life:results from the DESIR cohort. Ann Rheum Dis 2012;71(6):809-16.

3) Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012;64(5):1388-98.

4) Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2008;2008(1):CD002822. doi:10.1002/14651858.CD002822.pub3.

5) Machado P, Landewé R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS):defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70(1):47-53.

6) Glintborg B, Ostergaard M, Krogh NS, et al. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor:results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010;69(11):2002-8.

7) Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis:results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013;72(6):815-22.

8) Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis:the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21(12):2286-91.

9) Ramiro S, van der Heijde D, van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis:12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 2014;73(8):1455-61.

10) Poddubnyy D, Protopopov M, Haibel H, et al. High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis:results from the GErman SPondyloarthritis Inception Cohort. Ann Rheum Dis 2016;75(12):2114-8.

11) Sepriano A, Ramiro S, Wichuk S, et al. Disease activity is associated with spinal radiographic progression in axial spondyloarthritis independently of exposure to tumour necrosis factor inhibitors. Rheumatology (Oxford) 2021;60(1):461-2.

12) Kishimoto K, Asai S, Suzuki M, et al. Intervertebral fusion sites in patients with ankylosing spondylitis:a computed tomography study. Mod Rheumatol 2023:road065. doi:10.1093/mr/road065.

13) Webers C, Ortolan A, Sepriano A, et al. Efficacy and safety of biological DMARDs:a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis 2023;82(1):130-41.

14) Kroon FP, van der Burg LR, Ramiro S, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev 2015;2015(7):CD010952. doi:10.1002/14651858.CD010952.pub2.

15) Baraliakos X, Kiltz U, Peters S, et al. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. Rheumatology (Oxford) 2017;56(1):95-102.

16) Mishra D, Dhir V, Naidu GSRSNK, et al. Efficacy of a step-down regimen of oral prednisolone in axial spondyloarthritis:result of a double-blind randomized controlled trial (COBRA-AS Study). Rheumatology (Oxford) 2021;60(4):1932-41.

17) Nam B, Kim TH, Lee SW, et al. Efficacy and safety of intra-articular sacroiliac glucocorticoid injections in ankylosing spondylitis. J Clin Rheumatol 2022;28(1):e26-32. doi:10.1097/RHU.0000000000001584.

18) Braun J, Bollow M, Seyrekbasan F, et al. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis:clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol 1996;23(4):659-64.

19) Dhir V, Mishra D, Samanta J. Glucocorticoids in spondyloarthritis-systematic review and real-world analysis. Rheumatology (Oxford) 2021;60(10):4463-75.

20) Chen J, Lin S, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2014;(11):CD004800. doi:10.1002/14651858.CD004800.pub3.

21) Long Z, Deng Y, He Q, et al. Efficacy and safety of Iguratimod in the treatment of Ankylosing Spondylitis:a systematic review and meta-analysis of randomized controlled trials. Front Immunol 2023;14:993860. doi:10.3389/fimmu.2023.993860.

22) Fauny M, Moulin D, D'Amico F, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis 2020;79(9):1132-8.

23) van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1):a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet 2019;394(10214):2108-17.

24) van der Heijde D, Baraliakos X, Sieper J, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy:a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis 2022;81(11):1515-23.

25) Deodhar A, Van den Bosch F, Poddubnyy D, et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2022;400(10349):369-79.

26) Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 2022;386(4):316-26.

27) Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2022 update. Ann Rheum Dis 2023;82(1):3-18.

28) Kawahito Y, Morinobu A, Kaneko Y, et al. Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication. Mod Rheumatol 2023;33(1):21-35.

29) Kubiak EN, Moskovich R, Errico TJ, et al. Orthopaedic management of ankylosing spondylitis. J Am Acad Orthop Surg 2005;13(4):267-78.

30) Westerveld LA, Verlaan JJ, Oner FC. Spinal fractures in patients with ankylosing spinal disorders:a systematic review of the literature on treatment, neurological status and complications. Eur Spine J 2009;18(2):145-56.

31) Vander Cruyssen B, Muñoz-Gomariz E, Font P, et al. Hip involvement in ankylosing spondylitis:epidemiology and risk factors associated with hip replacement surgery. Rheumatology (Oxford) 2010;49(1):73-81.

32) Kishimoto K, Asai S, Suzuki M, et al. Age and symptoms at onset of ankylosing spondylitis in Japanese patients. Mod Rheumatol 2023;33(4):817-22.

33) Oommen AT, Hariharan TD, Chandy VJ, et al. Total hip arthroplasty in fused hips with spine stiffness in ankylosing spondylitis. World J Orthop 2021;12(12):970-82.